ASCO 2024 | Enhancing trial prescreening accuracy and timeliness with human-AI teams

Ravi Bharat Parikh • 1 Jun 2024

ASCO 2024

General

Ravi Bharat Parikh, MD, MPP, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, discusses findings from an interim analysis of a noninferiority trial utilizing natural language processing (NLP) algorithms to enhance trial prescreening accuracy and timeliness. Combining human involvement with artificial intelligence (AI) achieved noninferior overall accuracy in terms of trial prescreening. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Stock and Other Ownership Interests – GNS Healthcare; Google; Merck; Onc.AI; Thyme Care
Honoraria – Wake Forest School of Medicine
Consulting or Advisory Role – Archetype Therapeutics; Biofourmis; ConcertAI; Credit Suisse; G1 Therapeutics; Humana; Merck; NanOlogy; Thyme Care
Research Funding – Emerson Collective; Humana; Mendel AI; Prostate Cancer Foundation
Patents, Royalties, Other Intellectual Property – Technology to integrate patient-reported outcomes into electronic health record algorithms
Travel, Accommodations, Expenses – The Oncology Institute of Hope and Innovation